A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine
A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine
复制标题
DOI：
10.2337/diacare.27.7.1554
复制
发表时间：
2004-07-01
期刊：
影响因子：
16.2
通讯作者：
Tamborlane, WV
中科院分区：
文献类型：
--
作者：
Doyle, EA;Weinzimer, SA;Tamborlane, WV
目的 - 目前可用于每日多次注射 (MDI) 和连续皮下胰岛素输注 (CSII) 治疗的胰岛素类似物在儿科患者中的疗效尚未确定。我们在这项短期研究中的主要目的是比较 CSII 与使用甘精胰岛素的 MDI 在降低 1 型糖尿病儿童和青少年 HbA1c 水平方面的功效。 研究设计和方法 - 32 名患有 1 型糖尿病的青少年（8-21 岁）被随机分配接受每日一次甘精胰岛素和餐前/零食门冬胰岛素的 MDI 治疗或使用门冬胰岛素的 CSII 治疗。两组的剂量滴定均基于家庭自我监测血糖测量值和每月 HbA(1c)。治疗 16 周后，对 HbA(1c)、每日总胰岛素剂量 (TDD)、自我监测血糖读数和不良事件进行比较。 结果 - 尽管甘精胰岛素组没有显着变化（基线时 HbA(1c) 为 8.2%，16 周时为 8.1%），但随机分配至 CSII 组的青少年的 HbA(1c) 水平急剧下降，治疗后从 8.1% 降至 7.2%治疗 16 周（P < 0.02 与基线和
OBJECTIVE - The efficacy of the insulin analogs now available for Multiple daily injection (MDI) and continuous subcutaneous insulin infusion (CSII) therapy in type 1 diabetes has not yet been established in pediatric patients. Our principal aim in this short-term study was to compare the efficacy of CSII to MDI With glargine in lowering HbA, levels in children and adolescents with type 1 diabetes.RESEARCH DESIGN AND METHODS - Thirty-two youth with type 1 diabetes (age 8-21 years) were randomly assigned to receive either MDI treatment with once-daily glargine and premeal/snack insulin aspart or CSII with insulin aspart. Dose titration in both groups was based on home self-monitored blood glucose measurements and monthly HbA(1c). HbA(1c), total daily insulin dose (TDD), self-monitored blood glucose readings, and adverse events were compared after 16 weeks of therapy.RESULTS - while there was no significant change in the glargine group (HbA(1c) 8.2% at baseline vs. 8.1% at 16 weeks), youth randomized to CSII had a sharp reduction in HbA(1c) levels, from 8.1 to 7.2% after 16 weeks of therapy (P < 0.02 vs. baseline and